Mexico

Mexico

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.17 (0.16 - 0.19) 2019 Modelled IHME
0.18 (0.16 - 0.21) 2018 Modelled IHME
0.19 (0.17 - 0.21) 2017 Modelled IHME
0.19 (0.17 - 0.21) 2016 Modelled IHME
0.18 (0.16 - 0.20) 2015 Modelled IHME
0.19 (0.17 - 0.21) 2014 Modelled IHME
0.19 (0.17 - 0.21) 2013 Modelled IHME
0.2 (0.18 - 0.22) 2012 Modelled IHME
0.21 (0.18 - 0.23) 2011 Modelled IHME
0.21 (0.19 - 0.23) 2010 Modelled IHME
0.21 (0.19 - 0.24) 2009 Modelled IHME
0.21 (0.19 - 0.24) 2008 Modelled IHME
0.22 (0.20 - 0.24) 2007 Modelled IHME
0.22 (0.20 - 0.24) 2006 Modelled IHME
0.22 (0.20 - 0.24) 2005 Modelled IHME
0.23 (0.21 - 0.25) 2004 Modelled IHME
0.23 (0.21 - 0.25) 2003 Modelled IHME
0.24 (0.22 - 0.26) 2002 Modelled IHME
0.25 (0.23 - 0.27) 2001 Modelled IHME
0.25 (0.23 - 0.28) 2000 Modelled IHME
0.25 (0.23 - 0.28) 1999 Modelled IHME
0.26 (0.24 - 0.28) 1998 Modelled IHME
0.26 (0.24 - 0.29) 1997 Modelled IHME
0.26 (0.24 - 0.29) 1996 Modelled IHME
0.27 (0.24 - 0.29) 1995 Modelled IHME
0.27 (0.25 - 0.30) 1994 Modelled IHME
0.27 (0.25 - 0.30) 1993 Modelled IHME
0.28 (0.25 - 0.31) 1992 Modelled IHME
0.28 (0.25 - 0.32) 1991 Modelled IHME
0.29 (0.26 - 0.32) 1990 Modelled IHME
0.28 (0.20 - 0.36) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.02 (0.01 - 0.02) 2019 Modelled IHME
0.02 (0.01 - 0.02) 2018 Modelled IHME
0.02 (0.01 - 0.03) 2017 Modelled IHME
0.02 (0.01 - 0.03) 2016 Modelled IHME
0.02 (0.02 - 0.03) 2015 Modelled IHME
0.02 (0.02 - 0.03) 2014 Modelled IHME
0.02 (0.01 - 0.03) 2013 Modelled IHME
0.02 (0.01 - 0.02) 2012 Modelled IHME
0.02 (0.01 - 0.02) 2011 Modelled IHME
0.02 (0.01 - 0.02) 2010 Modelled IHME
0.02 (0.01 - 0.02) 2009 Modelled IHME
0.02 (0.01 - 0.02) 2008 Modelled IHME
0.02 (0.01 - 0.02) 2007 Modelled IHME
0.02 (0.01 - 0.02) 2006 Modelled IHME
0.02 (0.01 - 0.02) 2005 Modelled IHME
0.02 (0.01 - 0.02) 2004 Modelled IHME
0.02 (0.01 - 0.02) 2003 Modelled IHME
0.02 (0.01 - 0.02) 2002 Modelled IHME
0.01 (0.01 - 0.02) 2001 Modelled IHME
0.01 (0.01 - 0.02) 2000 Modelled IHME
0.02 (0.02 - 0.03) 1999 Modelled IHME
0.04 (0.03 - 0.05) 1998 Modelled IHME
0.06 (0.05 - 0.08) 1997 Modelled IHME
0.08 (0.06 - 0.10) 1996 Modelled IHME
0.09 (0.07 - 0.12) 1995 Modelled IHME
0.09 (0.07 - 0.12) 1994 Modelled IHME
0.1 (0.07 - 0.13) 1993 Modelled IHME
0.1 (0.08 - 0.13) 1992 Modelled IHME
0.1 (0.08 - 0.13) 1991 Modelled IHME
0.1 (0.08 - 0.13) 1990 Modelled IHME
0.04 (0.03 - 0.06) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
11 (9 - 14) 2019 Modelled IHME
11 (10 - 14) 2018 Modelled IHME
11 (10 - 14) 2017 Modelled IHME
11 (10 - 14) 2016 Modelled IHME
11 (10 - 14) 2015 Modelled IHME
11 (10 - 14) 2014 Modelled IHME
11 (10 - 14) 2013 Modelled IHME
11 (10 - 14) 2012 Modelled IHME
12 (10 - 14) 2011 Modelled IHME
12 (10 - 14) 2010 Modelled IHME
12 (10 - 14) 2009 Modelled IHME
12 (10 - 14) 2008 Modelled IHME
12 (10 - 15) 2007 Modelled IHME
13 (11 - 15) 2006 Modelled IHME
13 (11 - 15) 2005 Modelled IHME
13 (11 - 15) 2004 Modelled IHME
13 (11 - 15) 2003 Modelled IHME
13 (11 - 15) 2002 Modelled IHME
13 (11 - 15) 2001 Modelled IHME
13 (11 - 16) 2000 Modelled IHME
13 (11 - 16) 1999 Modelled IHME
13 (11 - 16) 1998 Modelled IHME
13 (11 - 16) 1997 Modelled IHME
13 (11 - 16) 1996 Modelled IHME
14 (11 - 16) 1995 Modelled IHME
14 (12 - 16) 1994 Modelled IHME
14 (12 - 16) 1993 Modelled IHME
14 (12 - 16) 1992 Modelled IHME
14 (12 - 16) 1991 Modelled IHME
14 (12 - 16) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
98 2018 Survey/reported WHO/UNICEF
98 2017 Survey/reported WHO/UNICEF
98 2016 Survey/reported WHO/UNICEF
98 2015 Survey/reported WHO/UNICEF
90 2014 Survey/reported WHO/UNICEF
82 2013 Survey/reported WHO/UNICEF
90 2012 Survey/reported WHO/UNICEF
98 2011 Survey/reported WHO/UNICEF
84 2010 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
55 2018 Survey/reported WHO/UNICEF
58 2017 Survey/reported WHO/UNICEF
93 2016 Survey/reported WHO/UNICEF
82 2015 Survey/reported WHO/UNICEF
84 2014 Survey/reported WHO/UNICEF
82 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
98 2011 Survey/reported WHO/UNICEF
93 2010 Survey/reported WHO/UNICEF
95 2009 Survey/reported WHO/UNICEF
97 2008 Survey/reported WHO/UNICEF
98 2007 Survey/reported WHO/UNICEF
98 2006 Survey/reported WHO/UNICEF
98 2005 Survey/reported WHO/UNICEF
98 2004 Survey/reported WHO/UNICEF
98 2003 Survey/reported WHO/UNICEF
97 2002 Survey/reported WHO/UNICEF
97 2001 Survey/reported WHO/UNICEF
97 2000 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
8 (6 - 12) 2015 Survey/reported Larney S et al, 2017
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
2005
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.66 (1.32 - 2.12) 2019 Modelled IHME
1.64 (1.31 - 2.10) 2018 Modelled IHME
1.62 (1.28 - 2.07) 2017 Modelled IHME
1.6 (1.27 - 2.04) 2016 Modelled IHME
1.58 (1.26 - 2.01) 2015 Modelled IHME
1.58 (1.26 - 2.02) 2014 Modelled IHME
1.58 (1.25 - 2.02) 2013 Modelled IHME
1.57 (1.25 - 2.02) 2012 Modelled IHME
1.57 (1.25 - 2.03) 2011 Modelled IHME
1.57 (1.24 - 2.04) 2010 Modelled IHME
1.51 (1.19 - 1.94) 2009 Modelled IHME
1.36 (1.07 - 1.74) 2008 Modelled IHME
1.19 (0.94 - 1.51) 2007 Modelled IHME
1.05 (0.83 - 1.32) 2006 Modelled IHME
0.98 (0.79 - 1.24) 2005 Modelled IHME
0.98 (0.78 - 1.23) 2004 Modelled IHME
0.97 (0.78 - 1.23) 2003 Modelled IHME
0.97 (0.77 - 1.23) 2002 Modelled IHME
0.97 (0.77 - 1.23) 2001 Modelled IHME
0.97 (0.77 - 1.23) 2000 Modelled IHME
0.97 (0.77 - 1.23) 1999 Modelled IHME
0.98 (0.78 - 1.24) 1998 Modelled IHME
0.99 (0.79 - 1.25) 1997 Modelled IHME
1 (0.80 - 1.27) 1996 Modelled IHME
1.02 (0.81 - 1.29) 1995 Modelled IHME
1.06 (0.84 - 1.35) 1994 Modelled IHME
1.15 (0.91 - 1.47) 1993 Modelled IHME
1.26 (0.99 - 1.63) 1992 Modelled IHME
1.4 (1.09 - 1.82) 1991 Modelled IHME
1.55 (1.21 - 2.03) 1990 Modelled IHME
1.1 (0.80 - 1.20) 2014 Modelled Gower et al, 2014
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1.4 (1.10 - 1.60) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
96 (93.70 - 97.50) 2019 Modelled Granados-Garcia V et al, 2019
95.3 (93.30 - 97.30) 2005 Modelled Degenhardt L et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
42 (37 - 46) 2019 Modelled IHME
42 (38 - 45) 2018 Modelled IHME
42 (38 - 45) 2017 Modelled IHME
42 (38 - 46) 2016 Modelled IHME
42 (38 - 46) 2015 Modelled IHME
42 (38 - 46) 2014 Modelled IHME
42 (38 - 46) 2013 Modelled IHME
43 (39 - 47) 2012 Modelled IHME
43 (39 - 47) 2011 Modelled IHME
43 (39 - 47) 2010 Modelled IHME
43 (39 - 47) 2009 Modelled IHME
43 (39 - 46) 2008 Modelled IHME
42 (39 - 46) 2007 Modelled IHME
42 (38 - 46) 2006 Modelled IHME
42 (38 - 46) 2005 Modelled IHME
42 (38 - 46) 2004 Modelled IHME
42 (38 - 46) 2003 Modelled IHME
42 (38 - 46) 2002 Modelled IHME
42 (39 - 46) 2001 Modelled IHME
42 (39 - 46) 2000 Modelled IHME
42 (39 - 46) 1999 Modelled IHME
42 (38 - 46) 1998 Modelled IHME
42 (39 - 46) 1997 Modelled IHME
42 (39 - 46) 1996 Modelled IHME
42 (38 - 46) 1995 Modelled IHME
42 (38 - 45) 1994 Modelled IHME
42 (38 - 45) 1993 Modelled IHME
42 (38 - 45) 1992 Modelled IHME
42 (38 - 45) 1991 Modelled IHME
41 (38 - 45) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (6 - 12) 2015 Survey/reported Larney S et al, 2017
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
2005
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Overview

HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.17 (%)
2019
(0.16 - 0.19(%))
IHME
HCV (RNA/cAg+)
1.66 (%)
2019
(1.32 - 2.12(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
2,125
2019
(1,714 - 2,622)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
13,737
2019
(11,294 - 16,865)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.02 (%)
2019, latest modelled
(0.01 - 0.02(%))
IHME

Prevalence PWID

HCV
96 (%)
2019, latest modelled
(93.70 - 97.50(%))
Granados-Garcia V et al, 2019

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
98 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
8
2015
(6 - 12)
Larney S et al, 2017
Eligible for HBV generic medicines
Eligible for HCV generic medicines